ALEMBIC PHARMACEUTICALS
|
ALEMBIC PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 31.33 | 17.40 | 26.50 | 58.33 | 43.97 |
| CEPS(Rs) | 45.20 | 31.41 | 41.09 | 66.05 | 50.82 |
| DPS(Rs) | 11.00 | 8.00 | 10.00 | 14.00 | 10.00 |
| Book NAV/Share(Rs) | 245.14 | 222.36 | 266.47 | 257.80 | 170.79 |
| Tax Rate(%) | 2.53 | 3.55 | 16.70 | 18.52 | 19.92 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.97 | 12.53 | 16.48 | 27.44 | 26.36 |
| EBIT Margin(%) | 11.05 | 7.16 | 12.12 | 25.66 | 22.30 |
| Pre Tax Margin(%) | 10.14 | 6.27 | 11.79 | 25.37 | 21.71 |
| PAT Margin (%) | 9.89 | 6.05 | 9.82 | 20.67 | 17.38 |
| Cash Profit Margin (%) | 14.26 | 10.92 | 15.22 | 24.07 | 20.80 |
| Performance Ratios | |||||
| ROA(%) | 9.93 | 5.15 | 7.34 | 16.95 | 14.37 |
| ROE(%) | 13.40 | 7.12 | 10.11 | 26.91 | 26.97 |
| ROCE(%) | 13.42 | 7.44 | 11.25 | 26.28 | 23.30 |
| Asset Turnover(x) | 1.00 | 0.85 | 0.75 | 0.82 | 0.83 |
| Sales/Fixed Asset(x) | 1.70 | 1.79 | 1.97 | 2.31 | 2.52 |
| Working Capital/Sales(x) | 3.84 | 4.44 | 4.64 | 3.93 | 6.48 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.59 | 0.56 | 0.51 | 0.43 | 0.40 |
| Receivable days | 60.69 | 59.84 | 39.75 | 41.06 | 53.64 |
| Inventory Days | 91.38 | 99.60 | 106.49 | 90.48 | 85.38 |
| Payable days | 150.62 | 148.04 | 173.51 | 187.92 | 223.04 |
| Valuation Parameters | |||||
| PER(x) | 31.35 | 28.50 | 27.97 | 16.55 | 12.14 |
| PCE(x) | 21.73 | 15.79 | 18.04 | 14.61 | 10.50 |
| Price/Book(x) | 4.01 | 2.23 | 2.78 | 3.74 | 3.12 |
| Yield(%) | 1.12 | 1.61 | 1.35 | 1.45 | 1.87 |
| EV/Net Sales(x) | 3.15 | 1.82 | 2.85 | 3.59 | 2.55 |
| EV/Core EBITDA(x) | 20.39 | 14.49 | 16.37 | 12.35 | 9.55 |
| EV/EBIT(x) | 28.50 | 25.45 | 23.53 | 13.99 | 11.42 |
| EV/CE(x) | 3.74 | 2.06 | 2.09 | 2.78 | 1.89 |
| M Cap / Sales | 3.10 | 1.72 | 2.75 | 3.52 | 2.18 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.19 | 6.54 | -1.62 | 17.10 | 17.06 |
| Core EBITDA Growth(%) | 35.24 | -23.09 | -41.02 | 27.66 | 39.07 |
| EBIT Growth(%) | 69.98 | -37.06 | -53.53 | 34.77 | 33.77 |
| PAT Growth(%) | 80.07 | -34.35 | -53.27 | 39.23 | 35.11 |
| EPS Growth(%) | 80.07 | -34.35 | -54.56 | 32.66 | 41.83 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.09 | 0.15 | 0.12 | 0.10 | 0.54 |
| Current Ratio(x) | 2.07 | 1.78 | 1.63 | 1.89 | 1.36 |
| Quick Ratio(x) | 0.99 | 0.88 | 0.75 | 0.93 | 0.76 |
| Interest Cover(x) | 12.24 | 8.07 | 36.27 | 86.40 | 37.81 |
| Total Debt/Mcap(x) | 0.02 | 0.07 | 0.04 | 0.03 | 0.17 |
Compare Financial Ratios of peers of ALEMBIC PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ALEMBIC PHARMACEUTICALS | ₹20,935.0 Cr | 1.4% | -3.5% | 34.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹440,830.0 Cr | -2.2% | 1.7% | 41.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹155,644.0 Cr | -4.6% | -1.6% | 45.8% | Stock Analytics | |
| CIPLA | ₹120,742.0 Cr | -2.8% | 1.8% | 15.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,366.0 Cr | -0.2% | 9.2% | 15.6% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,766.9 Cr | -0.9% | -0.1% | 41.1% | Stock Analytics | |
ALEMBIC PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALEMBIC PHARMACEUTICALS | 1.4% |
-3.5% |
34.9% |
| SENSEX | -0.5% |
-4.4% |
9.5% |
You may also like the below Video Courses
